Tibotec Pharmaceuticals Ltd.

Tibotec Bvba

Tibotech Bvba

Johan Hendrika Jozef Vingerhoets

Lieve Emma Jan Michiels

Inge Dierynck

Marie-Pierre T M M G De Bethune

Hilde Azijn

Sharon Kemp

The present invention is directed to the field of nucleic acid diagnostics and the identification of base variation in target nucleic acid sequences. More particularly, the present invention relates to the use of such genotypic characterization of a target population of HIV and the subsequent association, i.e., correlation, of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in drug development, i.e., drug discovery, drug design, drug modification, and therapy, treatment design, clinical management and diagnostic analysis.

Mutational profiles in HIV-1 protease correlated with phenotypic drug resistance

The present invention relates to methods and products for the evaluation of HIV treatment. In particular, molecular events at the HIV envelope protein and their effect on therapeutic efficacy of drugs are determined. The methods rely on providing HIV envelope nucleic acid material and evaluating a treatment either through genotyping or phenotyping. Said method may find use in multiple fields including diagnostics, drug screening, pharmacogenetics and drug development.

Methods and means for assessing HIV envelope inhibitor therapy

The present invention relates to methods and products for the evaluation of HIV treatment. The methods are based on evaluating molecular events at the HIV integrase resulting in altered therapeutic efficacy of the investigated compounds. The methods rely on providing an integrase gene and evaluating either through genotyping or phenotyping the integrase gene. The present invention relates to the fields of diagnostics, drug screening, pharmacogenetics and drug development.

Methods of assessing HIV integrase inhibitor therapy

Methods and products for the evaluation of HIV treatment are provided. The methods are based on evaluating molecular events at the HIV integrase resulting in altered therapeutic efficacy of tho investigated compounds. The methods rely on providing an integrase gene and evaluating either through integrase gene genotyping or phenotyping.

Growing community of inventors

Wijnegem, Belgium

Johan Hendrika Jozef Vingerhoets